Physicochemical and DMPK in silico models: Facilitating their use by medicinal chemists

Molecular Pharmaceutics

Volumn 10, Issue 4, 2013, Pages 1153-1161

  Ortwine, Daniel F ^a   Aliagas, Ignacio ^a  

^a GENENTECH INC   (United States)

Author keywords

ADMET; desktop modeling; hepatocyte; liver microsome; modeling; MPO; physicochemical; QSAR; review

Indexed keywords

ACCURACY; CALCULATION; COMPUTER MODEL; COMPUTER PROGRAM; DRUG DESIGN; DRUG PACKAGING; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; LIVER MICROSOME; MOLECULAR MODEL; MOLECULAR WEIGHT; PHYSICOCHEMICAL MODEL; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

COMPUTER SIMULATION; DRUG DESIGN; HUMANS; MODELS, THEORETICAL; SOFTWARE; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84875802857     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3006193     Document Type: Review

References (52)

1. Wenlock, M. C.; Austin, R. P.; Barton, P.; Davis, A. M.; Leeson, P. D. A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs J. Med. Chem. 2003, 46, 1250-1256
2. Faller, B.; Ottaviani, G.; Ertl, P.; Berellini, G.; Collis, A. Evolution of the physicochemical properties of marketed drugs: can history foretell the future? Drug Discovery Today 2011, 16, 976-984
3. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 2008, 51, 817-834
4. Gleeson, M. P.; Hersey, A.; Montanari, D.; Overington, J. Probing the links between in vitro potency, ADMET and physicochemical parameters Nat. Rev. Drug Discovery 2011, 10, 197-208
5. Scannell, J. W.; Blanckley, A.; Boldon, H.; Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency Nat. Rev. Drug Discovery 2012, 11, 191-200
6. Lee, P. H.; Cucurull-Sanchez, L.; Lu, J.; Du, Y. J. Development of in silico models for human liver microsomal stability J. Comput.-Aided Mol. Des. 2007, 21, 665-673
7. Molecular Drug Properties. Measurement and Prediction; Mannhold, R., Ed.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2008; p 468.
8. Desai, P. V.; Raub, T. J.; Blanco, M.-J. How hydrogen bonds impact P-glycoprotein transport and permeability Bioorg. Med. Chem. Lett. 2012, 22, 6540-6548
9. Gupta, R.; Gifford, E. M.; Liston, T.; Waller, C. L.; Hohman, M.; Bunin, B. A.; Ekins, S. Using Open Source Computational Tools For Predicting Human Metabolic Stability and Additional ADME/Tox Properties Drug Metab. Dispos. 2010, 38, 2083-2090
10. Aliagas, I.; Gobbi, A.; Heffron, T.; Lee, M.; Ortwine, D. F.; Zak, M.; Khojasteh, S. C. Modeling the Probability of a Compound Being Stable in Liver Microsome Assays: A Practical Tool for Drug Discovery, unpublished.
11. Zientek, M.; Stoner, C.; Ayscue, R.; Klug-McLeod, J.; Jiang, Y.; West, M.; Collins, C.; Ekins, S. Integrated in Silico-in Vitro Strategy for Addressing Cytochrome P450 3A4 Time-Dependent Inhibition Chem. Res. Toxicol. 2010, 23, 664-676
12. Pharmacokinetics and Metabolism in Drug Design; 2 nd ed.; Smith, D. A.; van de Waterbeemd, H.; Walker, D. K., Eds.; Wiley-VCH Verlag GmbH & Co., KGaA: Weinheim, Germany, 2006; Vol. 31; p 187.
13. Cruciani, G. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach J. Mol. Struct.: THEOCHEM 2000, 503, 17-30
14. Hewitt, M.; Cronin, M. T. D.; Enoch, S. J.; Madden, J. C.; Roberts, D. W.; Dearden, J. C. In silico prediction of aqueous solubility: the solubility challenge J. Chem. Inf. Model. 2009, 49, 2572-2587
15. Cruciani, G.; Carosati, E.; De Boeck, B.; Ethirajulu, K.; Mackie, C.; Howe, T.; Vianello, R. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist J. Med. Chem. 2005, 48, 6970-6979
16. Gao, H.; Yao, L.; Mathieu, H. W.; Zhang, Y.; Maurer, T. S.; Troutman, M. D.; Scott, D. O.; Ruggeri, R. B.; Lin, J. In silico modeling of nonspecific binding to human liver microsomes Drug Metab. Dispos. 2008, 36, 2130-2135
17. Gleeson, M. P. Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis J. Med. Chem. 2007, 50, 101-112
18. Gleeson, M. P.; Davis, A. M.; Chohan, K. K.; Paine, S. W.; Boyer, S.; Gavaghan, C. L.; Arnby, C. H.; Kankkonen, C.; Albertson, N. Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models J. Comput.-Aided Mol. Des. 2007, 21, 559-573
19. Sastry, G. M.; Dixon, S. L.; Sherman, W. Rapid shape-based ligand alignment and virtual screening method based on atom/feature-pair similarities and volume overlap scoring J. Chem. Inf. Model. 2011, 51, 2455-2466
20. Rush, T. S.; Grant, J. A.; Mosyak, L.; Nicholls, A. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction J. Med. Chem. 2005, 48, 1489-1495
21. Plewczynski, D.; Laźniewski, M.; Augustyniak, R.; Ginalski, K. Can we trust docking results? Evaluation of seven commonly used programs on PDBbind database J. Comput. Chem. 2011, 32, 742-755
22. Sushko, I.; Salmina, E.; Potemkin, V. A.; Poda, G.; Tetko, I. V. ToxAlerts: a Web server of structural alerts for toxic chemicals and compounds with potential adverse reactions J. Chem. Inf. Model. 2012, 52, 2310-2316
23. Thai, K.-M.; Ecker, G. F. Predictive models for HERG channel blockers: ligand-based and structure-based approaches Curr. Med. Chem. 2007, 14, 3003-3026
24. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26
25. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
26. Tarcsay, A.; Nyíri, K.; Keseru, G. M. Impact of Lipophilic Efficiency on Compound Quality J. Med. Chem. 2012, 55, 1252-1260
27. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties ACS Chem. Neurosci. 2010, 1, 435-449
28. Hill, A. P.; Young, R. J. Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity Drug Discovery Today 2010, 15, 648-655
29. Milletti, F.; Storchi, L.; Goracci, L.; Bendels, S.; Wagner, B.; Kansy, M.; Cruciani, G. Extending pKa prediction accuracy: high-throughput pKa measurements to understand pKa modulation of new chemical series Eur. J. Med. Chem. 2010, 45, 4270-4279
30. Segall, M. D. Multi-parameter optimization: identifying high quality compounds with a balance of properties Curr. Pharm. Des. 2012, 18, 1292-1310
31. Segall, M.; Champness, E.; Obrezanova, O.; Leeding, C. Beyond profiling: using ADMET models to guide decisions Chem. Biodiversity 2009, 6, 2144-2151
32. Obrezanova, O.; Segall, M. D. Gaussian processes for classification: QSAR modeling of ADMET and target activity J. Chem. Inf. Model. 2010, 50, 1053-1061
33. Forina, M.; Oliveri, P.; Lanteri, S.; Casale, M. Class-modeling techniques, classic and new, for old and new problems Chemom. Intell. Lab. Syst. 2008, 93, 132-148
34. Ritchie, T. J.; Ertl, P.; Lewis, R. The graphical representation of ADME-related molecule properties for medicinal chemists Drug Discovery Today 2010, 16, 65-72
35. Lobell, M.; Hendrix, M.; Hinzen, B.; Keldenich, J.; Meier, H.; Schmeck, C.; Schohe-Loop, R.; Wunberg, T.; Hillisch, A. In silico ADMET traffic lights as a tool for the prioritization of HTS hits ChemMedChem 2006, 1, 1229-1236
36. Bickerton, G. R.; Paolini, G. V.; Besnard, J.; Muresan, S.; Hopkins, A. L. Quantifying the chemical beauty of drugs Nat. Chem. 2012, 4, 90-98
37. Muchmore, S. W.; Edmunds, J. J.; Stewart, K. D.; Hajduk, P. J. Cheminformatic tools for medicinal chemists J. Med. Chem. 2010, 53, 4830-4841
38. Martin, Y. C. A bioavailability score J. Med. Chem. 2005, 48, 3164-3170
39. Ghose, A. K.; Herbertz, T.; Hudkins, R. L.; Dorsey, B. D.; Mallamo, J. P. Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery ACS Chem. Neurosci. 2012, 3, 50-68
40. Liu, L.; Paolo, J.; Dibarbosa, J.; Rong, H.; Reif, K.; Wong, H. Antiarthritis Effect of a Novel Bruton ' s Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism- Based Pharmacokinetic/ Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy Pharmacology 2011, 338, 154-163
41. Liu, L.; Halladay, J. S.; Shin, Y.; Wong, S.; Coraggio, M.; La, H.; Baumgardner, M.; Le, H.; Gopaul, S.; Boggs, J.; Kuebler, P.; Davis, J. C., Jr.; Liao, X. C.; Lubach, J. W.; Deese, A.; Sowell, C. G.; Currie, K. S.; Young, W. B.; Khojasteh, S. C.; Hop, C. E. C. A.; Wong, H. Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase Inhibitor Pharmacology 2011, 39, 1840-1849
42. Wager, T. T.; Liras, J. L.; Mente, S.; Trapa, P. Strategies to minimize CNS toxicity: in vitro high-throughput assays and computational modeling Expert Opin. Drug Metab. Toxicol. 2012, 8, 531-542
43. Heffron, T. P.; Salphati, L.; Alicke, B.; Cheong, J.; Dotson, J.; Edgar, K.; Goldsmith, R.; Gould, S. E.; Lee, L. B.; Lesnick, J. D.; Lewis, C.; Ndubaku, C.; Nonomiya, J.; Olivero, A. G.; Pang, J.; Plise, E. G.; Sideris, S.; Trapp, S.; Wallin, J.; Wang, L.; Zhang, X. The Design and Identification of Brain Penetrant Inhibitors of Phosphoinositide 3-Kinase α J. Med. Chem. 2012, 55, 8007-8020
44. Leeson, P. D.; St-Gallay, S. A. The influence of the "organizational factor" on compound quality in drug discovery Nat. Rev. Drug Discovery 2011, 10, 749-765
45. Willett, P.; Barnard, J. M.; Downs, G. M. Chemical Similarity Searching J. Chem. Inf. Model. 1998, 38, 983-996
46. Patterson, D. E.; Cramer, R. D.; Ferguson, A. M.; Clark, R. D.; Weinberger, L. E. Neighborhood behavior: a useful concept for validation of "molecular diversity" descriptors J. Med. Chem. 1996, 39, 3049-3059
47. Hopfinger, A. J.; Esposito, E. X.; LlinaÌs, A.; Glen, R. C.; Goodman, J. M. Findings of the challenge to predict aqueous solubility J. Chem. Inf. Model. 2009, 49, 1-5
48. Peng, Z.; Yang, B.; Mattaparti, S.; Shulok, T.; Thacher, T.; Kong, J.; Kostrowicki, J.; Hu, Q.; Na, J.; Zhou, J. Z.; Klatte, D.; Chao, B.; Ito, S.; Clark, J.; Sciammetta, N.; Coner, B.; Waller, C. Kuki PGVL Hub: An Integrated Desktop Tool for Medicinal Chemists to Streamline Design and Synthesis of Chemical Libraries and Singleton Compounds. In Methods in Molecular Biology; Zhou, J. Z., Ed.; Humana Press: Totowa, NJ, 2011; Vol. 685, pp 295-320.
49. Stewart, K. D.; Shiroda, M.; James, C. A. Drug Guru: a computer software program for drug design using medicinal chemistry rules Bioorg. Med. Chem. 2006, 14, 7011-7022
50. Hann, M. M.; Keserü, G. M. Finding the sweet spot in medicinal chemistry Nat. Rev. Drug Discovery 2012, 1039, 2012
51. Kozopas, K. M.; Yang, T.; Buchan, H. L.; Zhou, P.; Craig, R. W. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2 Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 3516-3520
52. Nicola, G.; Liu, T.; Gilson, M. K. Public domain databases for medicinal chemistry J. Med. Chem. 2012, 55, 6987-7002